Safety of a short-term infusion of fosnetupitant

arita Yukiya0 个研究点目标入组 70 人开始时间: 2023年2月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with solid tumors who have received fosnetupitant and are scheduled to receive it continuously.
•2)The age of patients on registration date is 18 years or older.
•3)ECOG PS 0,1 or 2.
•4)Patients whose latest test values within 28 days before registration(CTCAE v5.0) meet all of the following.
•(1)AST(GOT) Grade <=1
•(2)ALT(GPT) Grade <=1
•(3)Total bilirubin Grade <=1
•5)Patients who are able to comply with the protocol requirements
•6)Patients who have voluntarily given written consent after understanding the content of the informed consent document

•1)Patients with serious complications (interstitial pneumonia, pulmonary fibrosis, uncontrolled hypertension, uncontrolled diabetes, etc.)
•2)Patients with serious infections (including active tuberculosis)
•3)Patients with a history of allergic reactions of grade 3 or higher with CTCAE v5.0 to systemic therapy in the past
•4)Patients with a history of allergic reactions to fosnetupitant administered for 30 minutes
•5)Patients with severe allergic disease requiring continuous administration of antiallergic drugs or steroids
•6)Pregnant women, female patients who are breastfeeding or may be pregnant
•7)Patients who are not willing to use contraception
•8)Patients judged by the investigator to be inappropriate

发起方

arita Yukiya